Peer-influenced content. Sources you trust. No registration required. This is HCN.
Medical Professionals Reference (MPR)
This innovative intrauterine device may allow for improvements in discontinuation rates due to pain and bleeding and in expulsion rates.
Obstetrics & Gynecology March 12th 2025
Journal of the National Cancer Institute (JNCI)
A comprehensive analysis of 176,601 cancer cases demonstrates that long-acting reversible contraceptives offer a cancer risk profile comparable to oral contraceptives, with data showing a 20-30% reduction in gynecologic cancer risk and a modest increase in breast cancer risk that returns to baseline after cessation.
Obstetrics & Gynecology February 20th 2025
MDLinx
Medical bias can lead to missed diagnoses when physicians default to weight-related assumptions rather than conducting comprehensive evaluations.
Emergency Medicine February 5th 2025
Consultant360
Early detection of endometrial cancer through proper evaluation of postmenopausal bleeding can dramatically impact survival rates, with early-stage diagnosis offering significantly better outcomes.
Family Medicine/General Practice January 29th 2025
Cancer Therapy Advisor
Long-acting reversible contraceptives show varying effects on cancer risk, with some methods demonstrating protective effects against certain cancers while increasing risks for others.
Clinical trials reveal that osteoporosis screening is associated with five to six fewer fractures per 1,000 participants compared to usual care, providing concrete evidence for screening’s clinical value.
Endocrinology, Diabetes, Metabolism January 29th 2025